Why It Matters For years, the skyrocketing price of insulin has been at the forefront of America’s healthcare debate, and now it’s at the center of one of the most significant pharmaceutical pricing cases in history. The ongoing Insulin Pricing Multidistrict Litigation (MDL No. 3080) consolidates lawsuits against the nation’s three largest insulin manufacturers and three major pharmacy benefit managers (PBMs), who together control roughly 80% of the U.S. prescription drug ma

Artificial Intelligence (AI) is no longer just a buzzword—it’s reshaping nearly every industry. From healthcare to financial services, AI...

Pharmacies that paid for e-prescriptions routed through the Surescripts network may now have the opportunity to recover a portion of...

Class actions are often misunderstood. Many businesses assume they aren’t eligible, that recoveries are too small, or that the process is...